Literature DB >> 33935099

T217-Phosphorylation Exacerbates Tau Pathologies and Tau-Induced Cognitive Impairment.

Xin Wang1, Qian Liu1, Xiao-Guang Li2, Qiu-Zhi Zhou1, Dong-Qin Wu1, Shi-Hong Li1, Yan-Chao Liu1,3, Jian-Zhi Wang1,4.   

Abstract

BACKGROUND: Recent studies show that an increased T217-phosphorylation of tau in plasma could diagnose AD at an early stage with high accuracy and high specificity, while the potential toxic role of tau T217-phosphorylation is not known.
OBJECTIVE: To study the potential toxic role of tau T217-phosphorylation.
METHODS: We performed stereotactic brain injection, behavioral testing, immunohistochemistry and immunofluorescence, western blotting, Golgi staining, in vitro recombinant tau polymerization, and other measurements.
RESULTS: We first constructed tau T217-wild-type (T217), T217-phospho-mimic (T217E), and T217-non-phospho-mimic (T217A) plasmids or their virus vectors on the basis of wild-type tau. We found that expressing tau-T217E induced a significantly increased tau phosphorylation at multiple AD-associated sites with inhibited proteolysis and increased cleavage/fibrillization of tau, while expressing tau-T217A abolished the above changes of tau both in vitro and in vivo. By mutating T217E on tau-P301L, a dominant mutation identified in patients with frontotemporal dementia, we did not observe significant exacerbation of tau-P301L phosphorylation and cognitive impairment although the increased tau cleavage and propagation were shown.
CONCLUSION: T217-phosphorylation exacerbates wild-type tau hyperphosphorylation with aggravated tau cleavage/fibrillization and cognitive impairments, while overexpressing T217E on the basis P301L does not exacerbate tau phosphorylation or the P301L-induced cognitive deficits, although it aggravates tau cleavage and propagation.

Entities:  

Keywords:  Alzheimer’s disease; T217-phosphorylation; cognition; propagation; tau

Year:  2021        PMID: 33935099     DOI: 10.3233/JAD-210297

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  4 in total

1.  Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation.

Authors:  Kristie Stefanoska; Mehul Gajwani; Amanda R P Tan; Holly I Ahel; Prita R Asih; Alexander Volkerling; Anne Poljak; Arne Ittner
Journal:  Sci Adv       Date:  2022-07-06       Impact factor: 14.957

2.  (-)-Epicatechin Reduces Neuroinflammation, Protects Mitochondria Function, and Prevents Cognitive Impairment in Sepsis-Associated Encephalopathy.

Authors:  Jianmin Ling; Yanqing Wu; Xiaojing Zou; Yanmin Chang; Gang Li; Minghao Fang
Journal:  Oxid Med Cell Longev       Date:  2022-05-24       Impact factor: 7.310

Review 3.  Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.

Authors:  Shan Huang; Yan-Jiang Wang; Junhong Guo
Journal:  Neurosci Bull       Date:  2022-03-19       Impact factor: 5.271

4.  Association of NKAPL rs1635 With Cognitive Function in Early-Onset Schizophrenia.

Authors:  Yang Yang; Yi Su; Guiming Wei; Zhewei Kang; Zhe Lu; Yundan Liao; Tianlan Lu; Hao Yan; Weihua Yue; Ying Qin; Yuyanan Zhang
Journal:  Front Genet       Date:  2022-06-21       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.